

APPENDIX II
CLEAN VERSION OF THE ENTIRE SET OF PENDING CLAIMS
PURSUANT TO 37 CFR § 1.121 (c)(3)

1. A method, comprising:
 - a) providing;
 - i) a human presenting symptoms of sepsis, and
 - ii) a therapeutic composition comprising an antibody specific for SEQ ID NO:5; and
 - b) administering said therapeutic composition to said human under conditions such that at least one of said symptoms is reduced.
3. The method of Claim 1, wherein said human presents the symptoms of sepsis for a period in the range of approximately six to twelve hours prior to the administration of said therapeutic composition.
5. The method of Claim 1, wherein said antibody is polyclonal.
6. The method of Claim 1, wherein said antibody is monoclonal.
7. The method of Claim 1, wherein said antibody is not reactive with complement component C5.



ADDED PAGES FOR APPLICATION TRANSMITTAL
WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED

15. Relate Back

A. 35 U.S.C. § 119(e)

B. 35 U.S.C. §§ 120, 121 and 365(c)

☒ Amend the Specification by inserting before the first line the sentence: "This is a Continuation-In-Part of copending application(s) 09/387,671 filed on 08/31/99."

16. Further Inventorship Statement Where Benefit Of Prior Application(s) Claimed

a. This application discloses and claims additional disclosure by amendment and a new declaration or oath is being filed. With respect to the prior application, the inventor(s) in this application are ☒ the same.